Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
KRAS inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:FDA |
| gptkbp:ATCCode |
L01EG04
|
| gptkbp:brand |
gptkb:Krazati
|
| gptkbp:CASNumber |
2296729-00-3
|
| gptkbp:chemicalFormula |
C32H35ClFN7O2
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
adagrasib
|
| gptkbp:mechanismOfAction |
covalent inhibitor of KRAS G12C
|
| gptkbp:molecularWeight |
604.1 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue |
| gptkbp:target |
KRAS G12C mutation
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:KRAS
|
| gptkbp:bfsLayer |
5
|